SEC Form 4 · accession 0001209191-19-004449
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hung Do
Officer — Chief Science Officer
Period of report
Jan 15, 2019
Accepted (ET)
Jan 17, 2019 · 8:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 15, 2019 | M | 4,400 | $2.94 | A | 452,713 | D | |
| Common Stock | Jan 15, 2019 | M | 3,800 | $5.13 | A | 456,513 | D | |
| Common Stock | Jan 15, 2019 | S | 16,600 | $12.00 | D | 439,913 | D | |
| Common Stock | Jan 16, 2019 | M | 4,988 | $2.94 | A | 444,901 | D | |
| Common Stock | Jan 16, 2019 | M | 30,036 | $5.13 | A | 474,937 | D | |
| Common StockF2 | Jan 16, 2019 | S | 36,669 | $12.05 | D | 438,268 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $2.94 | Jan 15, 2019 | M | 4,400 | D | — | Jun 26, 2024 | Common Stock | 4,400 | 4,988 | D |
| Stock Options (right to buy)F4 | $5.13 | Jan 15, 2019 | M | 3,800 | D | — | Jan 3, 2027 | Common Stock | 3,800 | 66,821 | D |
| Stock Options (right to buy)F3 | $2.94 | Jan 16, 2019 | M | 4,988 | D | — | Jun 26, 2024 | Common Stock | 4,988 | 0 | D |
| Stock Options (right to buy)F4 | $5.13 | Jan 16, 2019 | M | 30,036 | D | — | Jan 3, 2027 | Common Stock | 30,036 | 36,785 | D |
Explanation of responses
- F1The sale of common stock was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018.
- F2This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.00 to $12.23. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3All of the options were fully vested and exercisable as of January 15, 2019.
- F4These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on January 3, 2018. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2018, with the final installment vesting on January 1, 2021.